Current issues with blood transfusions in sickle cell disease.
about
Implementation of a Process for Initial Transcranial Doppler Ultrasonography in Children With Sickle Cell Anemia.HCV in sickle cell diseaseMechanisms of sickle cell alloimmunizationCXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso-occlusion during hemolytic transfusion reactionsStroke in patients with sickle cell disease.Blood bank management of sickle cell patients at comprehensive sickle cell centers.Spleen R2 and R2* in iron-overloaded patients with sickle cell disease and thalassemia major.Transfusion practice in the intensive care unit: a 10-year analysis.Treatment for sickle cell disease in Africa: should we invest in haematopoietic stem cell transplantation?Alloimmunization in patients with sickle cell disease in French Guiana.Management of sickle cell disease in primary care.Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicityLiver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trialRed blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management.Use of cellular and plasma apheresis in the critically ill patient: Part II: Clinical indications and applications.Blood transfusion and 30-day readmission rate in adult patients hospitalized with sickle cell disease crisis.Protective effect of HLA-DQB1 alleles against alloimmunization in patients with sickle cell disease.The prevention and management of stroke in sickle cell anaemia.Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.The design, synthesis, and evaluation of organ-specific iron chelators.Impact of the 3,6,9-trioxadecyloxy group on desazadesferrithiocin analogue iron clearance and organ distribution.(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicityRegulatory B-cell compartment in transfused alloimmunized and non-alloimmunized patients with sickle cell diseaseDesign, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.Desferrithiocin analogues and nephrotoxicity.Indications and complications of transfusions in sickle cell disease.Challenges of alloimmunization in patients with haemoglobinopathies.Immune Regulation of sickle Cell Alloimmunization.Blood transfusion services for patients with sickle cell disease in Nigeria.Safety of pegylated interferon and ribavirin therapy for chronic hepatitis C in patients with sickle cell anemia.Alloimmunization in Patients with Sickle Cell Disease and Thalassemia: Experience of a Single Centre in Oman.Red Blood Cell Alloimmunization in Sickle Cell Disease Patients in Tanzania.Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease.Alloimmunization in sickle cell anemia in the era of extended red cell typing.NHLBI state of the science symposium in therapeutic apheresis: Knowledge gaps and research opportunities in the area of hematology-oncology.Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects.Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease.Anti-HI can cause a severe delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease patients.Guideline on the management of acute chest syndrome in sickle cell disease.Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.
P2860
Q27334023-CDC74734-7B55-4A54-93E0-A82675E3A1B4Q27487418-693396CE-B8AF-4DEF-8456-F480E7700EBDQ28083189-68858399-596F-453E-AE40-8FD58950962AQ30499303-9CCE10CF-A318-4BE3-8022-BBC3D6FFF033Q30650303-140E2C52-4013-4A58-AA73-BF931A9E17CFQ33450662-535E279D-4A9B-4353-B05C-225BE39DE224Q34004503-AAC3A362-DDE9-410C-82B5-A3A7FABDF99CQ34145971-D94F62BE-D6D9-44D3-A6DD-870F58E0C0CCQ34431739-38877F68-3C98-48FD-AD48-805B0647E30FQ35097675-70B3DE71-1C7B-4DC6-A68C-D0636934F6B9Q35611782-E931690A-B991-4787-8B95-57F29CBB5630Q35896606-0704959A-200C-434A-8451-DF6C8C721E69Q35987686-76A746F2-18F0-445D-9CB5-17DAF921A96AQ36106307-11A3531D-9418-4223-A005-F96E31839135Q36108261-8807BD59-73FA-46F6-AEFF-5CEE4293D8F4Q36161782-132FE80B-627C-4EFC-A307-00E7E6D38974Q36563588-5270E34D-E45A-4ADC-8468-93DD7B2AE206Q36627220-1D704C3A-E48E-4DDC-A9A2-6DC2B0BCC1DCQ36642048-FE4B4EEC-FD2D-4E91-88EE-A84A8A72584FQ36837342-E9097393-1E4A-4D46-BC90-BAA24BC1446EQ36857692-FED007E6-A87A-4F87-BBCA-E8685A026C74Q36899188-18862364-0685-4877-8C61-69256CEE7F9AQ37195103-8412363B-099E-46BB-9C66-22C7C271CD55Q37381807-BB99A0EC-2807-42EF-AA4D-DABD1F0F702BQ37423512-158B7071-E022-4ADF-B307-9F5B23E767E0Q38008292-FE49AF5D-473E-4742-9B18-83D46166B8F3Q38049189-AB8D3A80-B60C-4E32-BEC0-1246F8211B8FQ38928447-D28EE8B4-BDC1-4BF3-93EA-D80B9A29E1FCQ40836280-A48630D3-5B17-4FEB-A01B-610D9DA8CB51Q41140214-9978CEBF-1866-4EC8-9157-269BF64613E0Q41948001-6F988774-0D7C-4401-A493-42CF67EFCE6CQ42287014-C671EDCD-2902-4D8B-B9BF-FF628F99017DQ44973647-0C203F28-844C-494F-AF75-183C5D68E236Q45996396-8CE8CD5D-9576-4394-B69D-C26D9C7CDCADQ48491917-24EAA1A6-E159-4EBA-84FD-CFAC34217BCCQ50218898-51497C44-F3A1-4002-A80E-D8436B14D29EQ50231452-A2B90A00-9128-4254-9A56-ABC87F01713BQ50241611-A38A792F-57E4-4419-9FDE-8F205FD77031Q51645398-B6A4D672-9F38-460F-8DC9-1BBEBB18F500Q55427971-2E0B4122-16BA-4EFB-8575-DBC079902953
P2860
Current issues with blood transfusions in sickle cell disease.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Current issues with blood transfusions in sickle cell disease.
@ast
Current issues with blood transfusions in sickle cell disease.
@en
Current issues with blood transfusions in sickle cell disease.
@nl
type
label
Current issues with blood transfusions in sickle cell disease.
@ast
Current issues with blood transfusions in sickle cell disease.
@en
Current issues with blood transfusions in sickle cell disease.
@nl
prefLabel
Current issues with blood transfusions in sickle cell disease.
@ast
Current issues with blood transfusions in sickle cell disease.
@en
Current issues with blood transfusions in sickle cell disease.
@nl
P1476
Current issues with blood transfusions in sickle cell disease.
@en
P2093
Vichinsky EP
P356
10.1016/S0037-1963(01)90056-3
P433
P577
2001-01-01T00:00:00Z